![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BANYU PHARMACEUTICAL OBTAINS ADDITIONAL APPROVAL FOR NU-LOTAN TABLET
BANYU PHARMACEUTICAL OBTAINS ADDITIONAL APPROVAL FOR NU-LOTAN TABLET
April 24, 2006
Banyu Pharmaceutical has obtained additional approval for NU-LOTAN Tablet 25mg/ 50mg (losartan potassium), its proprietary agent for treating hypertension, from the Ministry of Health, Labor and Welfare. The agent is now available for the treatment of diabetic nephropathy (DN).
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=12375)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct